Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
ApexOnco Front Page
Recent articles
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
First-in-human study starts include radioligands from Akiram and Philogen.
The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.
A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.
The French group takes a shot at Perspective with its second bet on Orano Med.
The Hutchmed-originated savolitinib moves towards its first US approval.
Jazz's somewhat low-key SCLC drug scores its biggest win yet.
